Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Alinwell vs MadeMed

Alinwell
Site position #338

Lower grade

MadeMed
Site position #23

Higher grade

The verdict

MadeMed takes it — 80.4/100 to 61.2/100.

MadeMed grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Publishes its price at every single dose, so what a titrated dose costs is knowable on day one.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMadeMed +33
41
74
Dose & formulationMadeMed +15
75
90
Clinical oversightMadeMed +24
60
84
Labs & monitoringMadeMed +2
60
62
FulfillmentMadeMed +2
88
90
Contract termsMadeMed +33
55
88
Alinwell · top barMadeMed · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricAlinwellMadeMed
WeighScore61.2/10080.4/100
GradeCB−
Site position#338#23
Semaglutide$249/mo (standing rate, billed every 30 days; $149 covers the first month only)$239/mo quarterly (from $199/mo on 6 months)
Tirzepatide$299/mo (standing rate, billed every 30 days; $199 covers the first month only)$399/mo quarterly (from $369/mo on 6 months)
CoverageAll 50 states40 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualYesYes
Alinwell

Site position #338 · C

Strengths

  • Runs four GLP-1 lanes rather than two: injectable semaglutide, injectable tirzepatide, an oral GLP-1 and a microdose program
  • Care coaching and a dietitian visit are included in the plan panel at no separate charge, and a same-day clinician call is offered without a fee
  • Publishes certificates of analysis for its semaglutide and tirzepatide batches, and four compounding pharmacies are named on those certificates
  • Sells a large priced peptide catalog beside the GLP-1 lines, so a reader can see what the rest of the menu costs

Where it loses points

  • The advertised figure is a first-month price. Checkout labels $149 and $199 as “$100 off first month” and strikes $249 and $299 beside them
  • The three-month plan costs more per month than the advertised monthly price, because the advertised price is an introductory one
  • Three incompatible cancellation rules are live at once: 48 hours’ notice in the Terms, 30 days’ notice in the treatment FAQ, and “cancel anytime” on the checkout
  • The Terms and Privacy pages give the mailing address as “123 Example Street, Suite 100, Your City, WI, 92308” — an unedited template, and 92308 is a California ZIP
  • No clinician, medical director or medical group is named anywhere on the site
  • The pharmacy names appear only on batch certificates, and the site never states which one fills a given order or under what compounding class
MadeMed

Site position #23 · B−

Strengths

  • One flat price at every dose, published dose by dose — semaglutide 0.25–2.4mg, tirzepatide 2.5–15mg
  • LegitScript verified, with board-certified physician review and US compounding pharmacies
  • Full refund minus a $39 visit fee if you are not prescribed, stated before checkout
  • Oral semaglutide and oral tirzepatide alongside the injections; free overnight shipping with supplies

Where it loses points

  • The most expensive tirzepatide here at $399/mo quarterly
  • 40 states rather than nationwide
  • No published recurring lab program
  • Ships one vial every two months, a less flexible cadence than a monthly refill

Featured provider

MadeMed

MadeMed scores 80.4/100 (B−). Publishes its price at every single dose, so what a titrated dose costs is knowable on day one.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard